DCRI Awarded Federal Contract to Test New Anti-Infection Drugs

The Duke Clinical Research Institute will become one of three national sites to run early clinical trials of new anti-infection therapies under a contract announced by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

Duke CRI Launches Patient Registry for Lung Disease

Duke Clinical Research Institute has launched a patient registry to help researchers and clinicians identify, manage and study people who have a progressive lung disease called idiopathic pulmonary fibrosis.

Duke Picked for Hepatitis C Trials

The Duke Clinical Research Institute has been selected to run tests for a potential Hepatitis C cure. Benitec Biopharma Ltd., based in Sydney, Australia, is developing a drug to cure Hepatitis C and chose DCRI to run its Phase 1 and Phase 2 trials, the first in-human tests. Benitec has dubbed the drug TT-034.